After many years of success, EvidenceNetwork.ca is no longer in operation. We would like to thank everyone who has contributed to the organization over the past decade including our dedicated researchers, newspaper editors, readers and funders. However, now it is time to move onto new ways of looking at knowledge mobilization and policy. Should you have any questions, please feel free to contact Shannon Sampert at s.sampert@uwinnipeg.ca.

The newest report from Canada’s brand name drug makers on access to new drugs has one key message: compared to other countries, Canada goes slow and low. New drugs are slower to be covered by our provincial drug plans and the numbers of people who get access to new drugs are lower than in other countries.

A growing number of health professionals, patients, community groups and even politicians are calling for national pharmacare. But many Canadians likely wonder what pharmacare is and whether Canada is ready for it.

Employers in Canada spend an estimated 5 billion dollars a year on drug coverage for their employees. Yet, private plans are notoriously inefficient and they often cover higher priced drugs that are not necessarily better for consumers’ health, explains Alan Cassels.

Ontario spends $11-billion per year on prescription drugs. Nearly half of this is spent on medicines used by senior citizens, a group that receives public subsidies for nearly all of their prescription drug costs in Ontario.